Current oncology最新文献

{"title":"Evaluation of Cervical Cancer Screening in Japan: Challenges and Future Directions for Negative Intraepithelial Lesion or Malignancy/High-Risk Human Papillomavirus Positive Case Management.","authors":"Yasushi Umezaki, Asako Fukuda, Makiko Kurihara, Mariko Hashiguchi, Kaoru Okugawa, Masatoshi Yokoyama","doi":"10.3390/curroncol32060295","DOIUrl":"10.3390/curroncol32060295","url":null,"abstract":"<p><p>Cervical cancer screening is crucial for early detection and prevention. In Japan, women with negative intraepithelial lesion or malignancy (NILM) and high-risk human papillomavirus (HR-HPV) positivity are recommended retest for 12 months, rather than immediate colposcopy. International guidelines differ, and often prioritize early colposcopy for persistent HPV16/18 infections. This study evaluates Japan's current screening approach, and identifies areas for improvement. A retrospective cohort study analyzed cervical cancer screening data from Saga Prefecture (2019-2021), assessing follow-up adherence, colposcopy referral rates, and CIN2+ and CIN3+ detection among NILM/HR-HPV+ cases. Among 27,789 individuals screened, 2248 (8.1%) were NILM/HR-HPV+. Follow-up adherence after 12 months was 54.4%. Of these, 132 with cytological abnormalities underwent colposcopy, revealing CIN2+ in 27.3% of cases. Additionally, 561 women with persistent NILM/HR-HPV+ underwent colposcopy, with CIN2+ in 7.6% and CIN3+ in 3.9% of cases. Japan's current NILM/HR-HPV+ management strategy could delay the detection of high-grade cervical lesions. International guidelines favor earlier colposcopy referrals, particularly for HPV16/18+ cases. To improve cervical cancer prevention, Japan should consider a risk-based stratification model, enhance follow-up adherence, expand colposcopy access, and develop a national patient tracking system. Adopting primary HPV-based screening could attain the best global practices, facilitating earlier detection and reducing cervical cancer.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191841/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Burden and Trends of Gynecological Cancers in Asia from 1980 to 2021, with Projections to 2050: A Systematic Analysis for the Global Burden of Disease Study 2021.","authors":"Yang Yang, Run Miao, Haoyu He, Ning Zhang, Xingyu Wan, Yuzhou Gao, Dongmei Ji","doi":"10.3390/curroncol32060298","DOIUrl":"10.3390/curroncol32060298","url":null,"abstract":"<p><p>Gynecological cancers pose a significant threat to women's health. This study aimed to investigate the disease burden of cervical, uterine, and ovarian cancers in Asia from 1980 to 2021. The Global Burden of Disease 2021 database (GBD 2021) was used to conduct a cross-sectional study. The incidence, mortality rates, and disability-adjusted life years (DALYs) were obtained as indicators to estimate the burden. The effects of age, period, and cohort on the incidence of gynecological cancers were analyzed via the age-period-cohort web tool (APC-Web). The future trends of the gynecological cancer burden in Asia from 2025 to 2050 were predicted via a Bayesian age-period-cohort model. In 2021, cervical cancer exhibited the highest age-standardized mortality burden (3.1 deaths per 100,000; 95% UI: 2.7-3.4), whereas uterine cancer had the lowest (0.7 deaths per 100,000; 95% UI: 0.6-0.9). Geographically, South Asia has experienced the highest cervical cancer burden, with Seychelles, Mongolia, Cambodia, and Nepal ranking among the most affected nations. In contrast, Central Asia had the highest ovarian cancer burden, led by Georgia, followed by the United Arab Emirates, Seychelles, and Brunei Darussalam. Similarly, the uterine cancer burden was most pronounced in Central Asia, with Georgia, Armenia, Mauritius, and the United Arab Emirates exhibiting elevated rates. Finally, increasing trends in the burden of gynecological cancers were predicted across all age groups from 2025 to 2050, with women aged 60 to 64 years being the most affected. In conclusion, gynecological cancers are significant contributors to the disease burden in Asia. Improved early screening methods are essential to mitigate this increasing burden.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191526/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring Cancer Patients' and Caregivers' Perspectives and Knowledge Regarding Biomarker Testing in Canada.","authors":"Patil Mksyartinian, Selina Xu, Chrissa Barroma, Sandra Peláez, Barry D Stein","doi":"10.3390/curroncol32060292","DOIUrl":"10.3390/curroncol32060292","url":null,"abstract":"<p><p>While biomarker testing can provide various benefits for cancer patient outcomes, numerous challenges persist that cause inequities in access across Canada. An online survey consisting of 51 questions was disseminated to evaluate biomarker testing and precision medicine knowledge and experiences from Canadian patients and caregivers. Responses were recorded between June 2023 and January 2024 and assessed various aspects of the biomarker testing experience including the expectations and challenges of patients. Quantitative and qualitative analyses were conducted using Microsoft Excel and R for descriptive and correlative data analysis, respectively. Among the 74 responses, patients reported an overall moderate experience with positive outcomes for those who underwent biomarker testing, including changes to treatment plans and the shrinking of tumours. The main challenges identified included knowledge gaps, a lack of testing availability, turnaround time for results, and financial constraints, all of which contribute to the disparities in biomarker testing access. Qualitative analysis of responses further emphasized a strong patient desire for patient-centred care and collaborative decision-making for biomarker testing options and treatment planning. Addressing these challenges through increased education, policy advocacy, and advancing infrastructure can help to reduce interprovincial inequities in biomarker testing and contribute to improving cancer patient outcomes.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191459/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic Advances in Initially Unresectable Locally Advanced Intrahepatic Cholangiocarcinoma: Emerging Treatments and the Role of Liver Transplantation.","authors":"Sofia Lopiano, James V Guarrera, Keri E Lunsford","doi":"10.3390/curroncol32060293","DOIUrl":"10.3390/curroncol32060293","url":null,"abstract":"<p><p>Optimal curative therapy for intrahepatic cholangiocarcinoma (iCCA) involves hepatic resection; however, due to its insidious nature, iCCA frequently presents at advanced stages. Consequently, 70-80% of patients feature unresectable iCCA at presentation. Recent expansions in therapeutic options for locally advanced unresectable iCCA include immunotherapy, targeted chemotherapeutics, and liver-directed therapies. These have increased progression-free survival, enhanced response rates, and improved downstaging for resection. Liver transplant has also emerged as an alternative for patients whose tumors remain unresectable despite therapeutic response. Here, we explore emerging treatment options included in a multidisciplinary treatment paradigm to prolong survival in patients with initially unresectable locally advanced iCCA.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12192356/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Effects of RUNX1 Mutations on the Outcomes of Patients with Acute Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem-Cell Transplantation.","authors":"Wei-Jie Ran, Lan-Ping Xu, Xiao-Hui Zhang, Ying-Jun Chang, Xiao-Dong Mo, Yu-Qian Sun, Xiao-Jun Huang, Yu Wang","doi":"10.3390/curroncol32060294","DOIUrl":"10.3390/curroncol32060294","url":null,"abstract":"<p><p>It is reported that AML with RUNX1 mutations is associated with poorer response to conventional chemotherapy, lower rates of complete remission (CR), leukemia-free survival (LFS), and overall survival (OS). We aimed to evaluate the prognostic impact of RUNX1 mutations following allogeneic hematopoietic stem cell transplantation (allo-HSCT) by comparing clinical outcomes in AML patients with and without RUNX1 mutations. We retrospectively analyzed 91 AML patients (33 RUNX1+ and 58 RUNX1-) who received their first HSCT at Peking University People's Hospital. The median age of the cohort was 38 years (range: 6-64), with 73 patients (80%) receiving Haploidentical HSCT and 18 patients (20%) receiving sibling-matched allo-HSCT. In univariate analyses, no significant differences in survival outcomes were observed. For the RUNX1-mutation group and RUNX1-wild-type group, the 2-year cumulative incidence of relapse (CIR) was (12.6% vs. 7.6%, <i>p</i> = 0.472), the 2-year non-relapse mortality (NRM) rate was (9.6% vs. 7.2%, <i>p</i> = 0.747), the 2-year LFS was (77.8% vs. 85.2%, <i>p</i> = 0.426), and the 2-year OS rate was (85.9% vs. 92.7%, <i>p</i> = 0.397). We did not observe any negative impact of RUNX1 mutations on clinical outcomes, suggesting that allo-HSCT (especially Haplo-HSCT) may mitigate the adverse prognostic influence of RUNX1 mutations in AML.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12192008/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Canadian Recommendations for Germline Genetic Testing of Patients with Breast Cancer: A Call to Action.","authors":"Evan Weber, Carlos A Carmona-Gonzalez, Melanie Boucher, Andrea Eisen, Kara Laing, Jennifer Melvin, Kasmintan A Schrader, Sandeep Sehdev, Stephanie M Wong, Karen A Gelmon","doi":"10.3390/curroncol32060290","DOIUrl":"10.3390/curroncol32060290","url":null,"abstract":"<p><p>Pathogenic variants in breast cancer predisposition genes are associated with poor clinical outcomes but also offer an opportunity for more individualized therapeutic pathways. Given increasing knowledge, improvements in germline genetic testing efficiency, and the availability of novel systemic targeted treatment options, the importance of appropriately identifying patients for testing has never been greater. A pan-Canadian expert working group (EWG) consisting of 10 healthcare professionals (HCPs) was convened to review recent international guidelines for germline genetic testing in breast cancer and develop Canadian recommendations. The group identified four clinical questions to address which patients should undergo testing, what approaches should be used, how patients should be counselled, and what steps are needed for implementation. In response to these questions, the EWG agreed upon 12 recommendations that emphasized broader incorporation of germline genetic testing and more standardized, streamlined testing and counselling approaches. The group also offered multiple suggestions to support effective and equitable implementation across Canada. These recommendations provide guidance for HCPs and represent a call to action for the Canadian government and other organizations to support genetic testing pathways, drug access, and ultimately improved outcomes for patients with breast cancer and their families.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191570/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From CBCT to MR-Linac in Image-Guided Prostate Cancer Radiotherapy Towards Treatment Personalization.","authors":"Florentina Larisa Coc, Loredana G Marcu","doi":"10.3390/curroncol32060291","DOIUrl":"10.3390/curroncol32060291","url":null,"abstract":"<p><p><b>Purpose</b>: Image-guided radiotherapy (IGRT) has been widely implemented in the treatment of prostate cancer, offering a number of advantages regarding the precision of dose delivery. This study provides an overview of factors, clinical and physical alike, that increase treatment accuracy in prostate cancer radiotherapy in the context of IGRT. The following aspects are explored based on recent literature: the radiotherapy technique used in conjunction with IGRT, the type and frequency of IGRT, the impact of radiotherapy technique/IGRT on target dosimetry and organs at risk, the influence of IGRT on planning target volume margins, the impact of treatment time on dosimetric outcome and clinical outcomes using IGRT repositioning or an online adaptive plan. <b>Methods</b>: A systematic search of the literature was conducted within Pubmed/Medline databases to find relevant studies. Of the 152 articles fulfilling the initial search criteria, 79 were selected for final analysis. <b>Results</b>: The frequency of image guidance, the treatment regimen and the radiation technique are important factors that contribute to the optimization and personalization of the treatment plan. The daily anatomy and volume of the bladder and rectum can vary considerably, which can significantly impact the dosimetric effects on these organs. When used in conjunction with volumetric modulated arc therapy, IGRT allows for shaping the dose distribution to avoid nearby critical structures such as the bladder and rectum. <b>Conclusions</b>: Precise tumor targeting via IGRT can result in fewer geometric uncertainties, thereby improving treatment outcome both in terms of superior target coverage and sparing organs at risk.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191943/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing Cancer Patient Navigation: Lessons from an Evaluation of Navigation Services in Alberta, Canada.","authors":"Linda Watson, Se'era May Anstruther, Claire Link, Siwei Qi, Kathryn Burrows, Michelle Lack, Krista Rawson, Andrea DeIure","doi":"10.3390/curroncol32050287","DOIUrl":"10.3390/curroncol32050287","url":null,"abstract":"<p><p>Cancer patient navigation has emerged as a patient-centric intervention enabling equitable cancer care, by mitigating barriers patients encounter throughout their cancer journey. Cancer Care Alberta (CCA) implemented a professional navigation model over a decade ago and commissioned a program evaluation in response to evolving operational demands. The objectives were (1) to better understand the current state of CCA's cancer patient navigation program; (2) to explore the need for other specialized streams; and (3) to provide key recommendations to strengthen and grow the program. A mixed methods approach, including a survey, administrative data, and semi-structured interviews, captured patient-, staff-, and system-level insights. Findings revealed difficulties in identifying complex patients needing navigation, along with inconsistencies regarding intake practices, program awareness, referral pathways, standardized workflows, and a lack of programmatic supports, which contributed to variability in service delivery. A need for enhanced palliative navigation support also emerged. Approximately 25% of surveyed patients reported being unable to access perceived needed support before their first oncology consultation. These findings underscore the importance of early, targeted navigation for equity-deserving populations. Recommendations include harmonizing program structure, refining navigator roles, expanding navigation streams, standardizing processes, and enhancing equity-focused competencies. These findings offer a roadmap with which to improve person-centered cancer care.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 5","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12110542/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144149726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nonregular Physical Activity and Handgrip Strength as Indicators of Fatigue and Psychological Distress in Cancer Survivors.","authors":"Ilaria Pepe, Alessandro Petrelli, Francesco Fischetti, Carla Minoia, Stefania Morsanuto, Livica Talaba, Stefania Cataldi, Gianpiero Greco","doi":"10.3390/curroncol32050289","DOIUrl":"10.3390/curroncol32050289","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Cancer survivors who do not engage in regular physical activity often experience persistent psychological distress and fatigue, which can significantly impact their quality of life. While handgrip strength (HGS) is recognized as an indicator of overall health and physical resilience, the combined role of HGS and physical inactivity in predicting psychological distress and fatigue in this population remains unclear. This study aimed to examine the relationships between self-reported physical inactivity, HGS, and psychological distress, specifically depressive symptoms, anxiety, and cancer-related fatigue (CRF), in physically inactive cancer survivors.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This cross-sectional study included 42 physically inactive cancer survivors (mean age = 63.2 years, SD = 8.96) recruited from the Cancer Institute (IRCCS) in Bari, Italy. Physical inactivity was quantified based on self-reported weekly physical activity minutes, with all participants engaging in less than 150 min per week. The participants underwent HGS assessment and completed validated psychological measures, including the Beck Depression Inventory (BDI), the State-Trait Anxiety Inventory (STAI-Y1 and STAI-Y2), and the Fatigue Severity Scale (FSS).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Bivariate correlations were examined via Spearman's rank correlation coefficients, and multiple linear regression analyses were performed to identify independent predictors of psychological distress and fatigue, adjusting for covariates such as age, sex, cancer type, and time since treatment completion. Both lower HGS and greater physical inactivity were significantly correlated with greater depressive symptoms (HGS: ρ = -0.524, &lt;i&gt;p&lt;/i&gt; &lt; 0.001; physical inactivity: ρ = -0.662, &lt;i&gt;p&lt;/i&gt; &lt; 0.001), greater fatigue severity (HGS: ρ = -0.599, &lt;i&gt;p&lt;/i&gt; &lt; 0.001; physical inactivity: ρ = -0.662, &lt;i&gt;p&lt;/i&gt; &lt; 0.001), and increased trait anxiety (HGS: ρ = -0.532, &lt;i&gt;p&lt;/i&gt; &lt; 0.001; physical inactivity: ρ = -0.701, &lt;i&gt;p&lt;/i&gt; &lt; 0.001). No significant associations were found between physical inactivity or HGS and state anxiety (&lt;i&gt;p&lt;/i&gt; &gt; 0.05). Multiple regression analyses confirmed that both HGS and physical inactivity independently predicted depressive symptoms (HGS: β = -0.435, &lt;i&gt;p&lt;/i&gt; = 0.009; physical inactivity: β = -0.518, &lt;i&gt;p&lt;/i&gt; = 0.002), trait anxiety (HGS: β = -0.313, &lt;i&gt;p&lt;/i&gt; = 0.038; physical inactivity: β = -0.549, &lt;i&gt;p&lt;/i&gt; &lt; 0.001), and fatigue (HGS: β = -0.324, &lt;i&gt;p&lt;/i&gt; = 0.033; physical inactivity: β = -0.565, &lt;i&gt;p&lt;/i&gt; &lt; 0.001), even after adjusting for covariates. Low physical activity and reduced muscle strength independently predict psychological distress and fatigue in cancer survivors.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;These findings highlight the potential exacerbating role of physical inactivity in both physical and psychological vulnerability, underscoring the need for interventions promoting regular exercise. Integrating strength assessments an","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 5","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12109983/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144149702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Desmoid Dilemma: Challenges and Opportunities in Assessing Tumor Burden and Therapeutic Response.","authors":"Yu-Cherng Chang, Bryan Nixon, Felipe Souza, Fabiano Nassar Cardoso, Etan Dayan, Erik J Geiger, Andrew Rosenberg, Gina D'Amato, Ty Subhawong","doi":"10.3390/curroncol32050288","DOIUrl":"10.3390/curroncol32050288","url":null,"abstract":"<p><p>Desmoid tumors are rare, locally invasive soft-tissue tumors with unpredictable clinical behavior. Imaging plays a crucial role in their diagnosis, measurement of disease burden, and assessment of treatment response. However, desmoid tumors' unique imaging features present challenges to conventional imaging metrics. The heterogeneous nature of these tumors, with a variable composition (fibrous, myxoid, or cellular), complicates accurate delineation of tumor boundaries and volumetric assessment. Furthermore, desmoid tumors can demonstrate prolonged stability or spontaneous regression, and biologic quiescence is often manifested by collagenization rather than bulk size reduction, making traditional size-based response criteria, such as Response Evaluation Criteria in Solid Tumors (RECIST), suboptimal. To overcome these limitations, advanced imaging techniques offer promising opportunities. Functional and parametric imaging methods, such as diffusion-weighted MRI, dynamic contrast-enhanced MRI, and T2 relaxometry, can provide insights into tumor cellularity and maturation. Radiomics and artificial intelligence approaches may enhance quantitative analysis by extracting and correlating complex imaging features with biological behavior. Moreover, imaging biomarkers could facilitate earlier detection of treatment efficacy or resistance, enabling tailored therapy. By integrating advanced imaging into clinical practice, it may be possible to refine the evaluation of disease burden and treatment response, ultimately improving the management and outcomes of patients with desmoid tumors.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 5","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12110604/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144149794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}